Compare Heron Therapeutics Inc (HRTX) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Innodata Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Innodata Inc trades at $62.04 (market cap $2.10B). The key difference: Innodata Inc is far larger — about 30.9× Heron Therapeutics Inc's market cap, and Innodata Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Innodata Inc for 19 Days on average.
| HRTX | INOD | |
|---|---|---|
Market Cap | $68.01M | $2.10B |
Volume | 1,891,941 | 989,493 |
Sector | Health | Technology |
52-Week High | $1.49 | $121.50 |
52-Week Low | $0.27 | $34.45 |
Typical Hold Time | 35 Days | 19 Days |
Enterprise Value | $174.75M | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
INOD is trading at $61.20, down 3.49% today, showing bearish technical signals despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters with Q1 2026 EPS of $0.42 versus $0.13 expected. Revenue growth accelerated from $252M in 2025 to $317M in 2026, while net profit margins improved from 12.78% to 14.65%. Recent developments include the opening of a motion-capture AI lab and board appointments strengthening cybersecurity expertise.
The stock presents a growth opportunity with strong AI data engineering positioning and expanding margins, but faces headwinds from premium valuation (P/E 47.43) and technical weakness. Key risks include customer concentration and competitive pressures in the AI services sector. Analyst consensus remains bullish with 4 buy ratings versus 2 holds, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
